Eyenovia, Inc. – NASDAQ:EYEN
Eyenovia stock price today
$16.19
+16.09
+17086.84%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Eyenovia stock price monthly change
-91.22%
month
Eyenovia stock price quarterly change
-91.22%
quarter
Eyenovia stock price yearly change
-95.48%
year
Eyenovia key metrics
Market Cap | 9.41M |
Enterprise value | 120.18M |
P/E | -5.1 |
EV/Sales | N/A |
EV/EBITDA | -2.95 |
Price/Sales | N/A |
Price/Book | 7.96 |
PEG ratio | 0.13 |
EPS | -0.75 |
Revenue | N/A |
EBITDA | -27.30M |
Income | -32.44M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEyenovia stock price history
Eyenovia stock forecast
Eyenovia financial statements
| Jun 2023 | 0 | -6.21M | |
|---|---|---|---|
| Sep 2023 | 1.19K | -7.33M | -612582.05% |
| Dec 2023 | 2.58K | -7.96M | -307730.28% |
| Mar 2024 | 4.99K | -10.92M | -218748.27% |
| Mar 2024 | 4.99K | -10.92M | -218748.27% |
|---|---|---|---|
| Sep 2025 | 2.83M | -17.85M | -630.02% |
| Oct 2025 | 2.6M | -5.59M | -215.11% |
| Dec 2025 | 3.8M | -4.66M | -122.65% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 29346899 | 18.82M | 64.15% |
|---|---|---|---|
| Sep 2023 | 34865437 | 19.08M | 54.74% |
| Dec 2023 | 28779374 | 19.78M | 68.73% |
| Mar 2024 | 26177163 | 24.35M | 93.06% |
| Jun 2023 | -4.71M | -1.28M | 5.00M |
|---|---|---|---|
| Sep 2023 | -5.84M | -1.70M | 10.77M |
| Dec 2023 | -6.32M | -145.23K | 614.27K |
| Mar 2024 | -9.89M | -114.10K | 3.13M |
Eyenovia alternative data
| Aug 2023 | 41 |
|---|---|
| Sep 2023 | 41 |
| Oct 2023 | 41 |
| Nov 2023 | 41 |
| Dec 2023 | 41 |
| Jan 2024 | 41 |
| Feb 2024 | 41 |
| Mar 2024 | 57 |
| Apr 2024 | 57 |
| May 2024 | 57 |
| Jun 2024 | 57 |
| Jul 2024 | 57 |
Eyenovia other data
2.50%
-6.85%
of EYEN is owned by hedge funds
17
-10
841.11K
-2.39M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 0 | 140000 |
| May 2023 | 113747 | 90000 |
| Aug 2023 | 75000 | 0 |
| Sep 2023 | 7357 | 0 |
| Dec 2023 | 4890 | 0 |
| Mar 2024 | 160717 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GRANT STUART M. 10 percent owner | Common stock, par value $0.0001 | 100,000 | $0.98 | $98,000 | ||
Purchase | GRANT STUART M. 10 percent owner | Common stock, par value $0.0001 | 50,000 | $1.23 | $61,500 | ||
Purchase | GRANT STUART M. 10 percent owner | Common stock, par value $0.0001 | 10,717 | $1.58 | $16,911 | ||
Purchase | ROWE MICHAEL M director, officer.. | Common Stock, par value $.0001 | 4,890 | $1.36 | $6,650 | ||
Purchase | STRAHLMAN ELLEN R director | Common Stock, par value $.0001 | 4,820 | $1.68 | $8,098 | ||
Purchase | ROWE MICHAEL M director, officer.. | Common Stock, par value $.0001 | 1,400 | $1.66 | $2,324 | ||
Purchase | ROWE MICHAEL M director, officer.. | Common Stock, par value $.0001 | 1,137 | $1.75 | $1,990 | ||
Purchase | GRANT STUART M. 10 percent owner | Common Stock, par value $0.0001 | 30,000 | $1.87 | $56,100 | ||
Purchase | GRANT STUART M. 10 percent owner | Common stock, par value $0.0001 | 45,000 | $1.91 | $85,815 | ||
Purchase | GANDOLFO JOHN P officer: Chief Financial Officer | Common Stock, par value $.0001 | 2,000 | $2.79 | $5,580 |
| Patent |
|---|
Grant Utility: Ophthalmic drug delivery Filling date: 6 Nov 2020 Issue date: 26 Jul 2022 |
Application Filling date: 2 Mar 2020 Issue date: 28 Apr 2022 |
Grant Filling date: 29 Jun 2016 Issue date: 29 Mar 2022 |
Application SPRAY EJECTOR MECHANISMS AND DEVICES PROVIDING CHARGE ISOLATION AND CONTROLLABLE DROPLET CHARGE, AND LOW DOSAGE VOLUME OPHTHALMIC ADMINISTRATION Filling date: 9 Aug 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 7 Jun 2019 Issue date: 1 Mar 2022 |
Application Filling date: 13 May 2021 Issue date: 30 Dec 2021 |
Application Filling date: 26 Apr 2021 Issue date: 23 Dec 2021 |
Application Filling date: 6 Nov 2020 Issue date: 23 Sep 2021 |
Grant Utility: Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume ophthalmic administration Filling date: 10 Apr 2013 Issue date: 7 Sep 2021 |
Application Filling date: 11 Dec 2020 Issue date: 17 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 17 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 18 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 13 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH (1974) Chief Executive Officer, Pres, Chief Medical Officer & Director | $731,910 |
Mr. John P. Gandolfo CPA (1961) Chief Financial Officer & Sec. | $506,110 |
| Mr. Michael M. Rowe (1962) Chief Operating Officer | $368,130 |
Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market Place
Eyenovia: Countdown To May 8, 2023
Hoping Eyenovia Has The Aye Votes From The FDA In The Near Future (Rating Downgrade)
Eyenovia: I Can See You Better - Now
Eyenovia: FDA Setback Is Big Opportunity For Investors
Eyenovia: Can You See Me Now?
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
-
What's the price of Eyenovia stock today?
One share of Eyenovia stock can currently be purchased for approximately $16.19.
-
When is Eyenovia's next earnings date?
Unfortunately, Eyenovia's (EYEN) next earnings date is currently unknown.
-
Does Eyenovia pay dividends?
No, Eyenovia does not pay dividends.
-
How much money does Eyenovia make?
Eyenovia has a market capitalization of 9.41M.
-
What is Eyenovia's stock symbol?
Eyenovia, Inc. is traded on the NASDAQ under the ticker symbol "EYEN".
-
What is Eyenovia's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eyenovia?
Shares of Eyenovia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eyenovia's key executives?
Eyenovia's management team includes the following people:
- Dr. Tsontcho Ianchulev M.P.H., M.D., MPH Chief Executive Officer, Pres, Chief Medical Officer & Director(age: 51, pay: $731,910)
- Mr. John P. Gandolfo CPA Chief Financial Officer & Sec.(age: 64, pay: $506,110)
- Mr. Michael M. Rowe Chief Operating Officer(age: 63, pay: $368,130)
-
How many employees does Eyenovia have?
As Jul 2024, Eyenovia employs 57 workers.
-
When Eyenovia went public?
Eyenovia, Inc. is publicly traded company for more then 7 years since IPO on 25 Jan 2018.
-
What is Eyenovia's official website?
The official website for Eyenovia is eyenovia.com.
-
Where are Eyenovia's headquarters?
Eyenovia is headquartered at 295 Madison Avenue, New York, NY.
-
How can i contact Eyenovia?
Eyenovia's mailing address is 295 Madison Avenue, New York, NY and company can be reached via phone at +91 72891117.
Eyenovia company profile:
Eyenovia, Inc.
eyenovia.comExchange:
NASDAQ
Full time employees:
57
Industry:
Biotechnology
Sector:
Healthcare
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
295 Madison Avenue
New York, NY 10017
New York, NY 10017
CIK: 0001682639
ISIN: US30234E1047
CUSIP: 30234E104
